NCT06471946 VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
| NCT ID | NCT06471946 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Navy General Hospital, Beijing |
| Condition | Higher-risk Myelodysplastic Syndromes |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2029-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 54 participants in total. It began in 2024-10-01 with a primary completion date of 2029-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
Eligibility Criteria
Inclusion Criteria: * The patient should, in the investigator's opinion, be able to meet all clinical trial requirements. * The patient is willing and able to adhere to the study visit schedule and other protocol requirements. * The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO). Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.
Contact & Investigator
Liren Qian, PhD
PRINCIPAL INVESTIGATOR
Navy General Hospital, Beijing
Frequently Asked Questions
Who can join the NCT06471946 clinical trial?
This trial is open to participants of all sexes, aged 70 Years or older, studying Higher-risk Myelodysplastic Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06471946 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06471946 currently recruiting?
Yes, NCT06471946 is actively recruiting participants. Contact the research team at qlr2007@126.com for enrollment information.
Where is the NCT06471946 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06471946 clinical trial?
NCT06471946 is sponsored by Navy General Hospital, Beijing. The principal investigator is Liren Qian, PhD at Navy General Hospital, Beijing. The trial plans to enroll 54 participants.